64th ASH Annual Meeting and Exposition: 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT

Symposia: Cellular Immunotherapies: Early Phase and Investigational Therapies Oral and Poster Abstracts
Oral

Research, clinical trials, Biological therapies, Viral, Iron Deficiency, adult, Translational Research, elderly, Clinical Research, Plasma Cell Disorders, Chimeric Antigen Receptor (CAR)-T Cell Therapies, GVHD, Diseases, Immune Disorders, Therapies, Immunotherapy, Infectious Diseases, Lymphoid Malignancies, Infusion, Myeloid Malignancies, Technology and Procedures, gene editing, Study Population, Human, Transplantation

Great Hall AD (Ernest N. Morial Convention Center)

Moderators:

Damian J. Green, MD, Fred Hutchinson Cancer Research Center and Hongtao Liu, MD, PhD, University of Chicago

Disclosures:

Green: BMS: Membership on an entity's Board of Directors or advisory committees, Research Funding; Cellectar Biosciences: Research Funding; GSK: Membership on an entity's Board of Directors or advisory committees; Janssen Biotech: Membership on an entity's Board of Directors or advisory committees, Research Funding; Neoleukin Therapeutics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Seattle Genetics: Membership on an entity's Board of Directors or advisory committees, Research Funding; Juno Therapeutics: Patents & Royalties, Research Funding; SpringWorks Therapeutics: Research Funding; Legend Biotech: Membership on an entity's Board of Directors or advisory committees. Liu: Agios; Pfizer; Nkarta; CTI Biopharm; Servier: Honoraria, Other: Advisory board meeting ; NGM Biopharma: Consultancy; Miltenyi Biotec: Research Funding; SITC; Academy for Continued Healthcare Learning (ACHL): Honoraria, Other: Speaker/Lecturer.

CAR studies focused on MM and post allo-HCT T cell therapies (DLI, CTL etc.)

4:00 PM

361

KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation

Saad Usmani, MD¹, Krina Patel, MD, MSc², Parameswaran Hari, MD, MRCP³, Jesus Berdeja, MD⁴, Melissa Alsina, MD**⁵, Ravi Vij, MD, MBBS⁶, Noopur Raje, MD⁷, Xavier Leleu, MD, PhD⁸, Madhav Dhodapkar, MBBS⁹, Ran Reshef, MD, MSc¹⁰, Anna Truppel-Hartmann, MD¹¹^*, Debashree Basudhar, PhD¹²^*, Ethan Thompson, PhD¹²^*, Xirong Zheng, PhD¹²^*, Revathi Ananthakrishnan, PhD¹²^*, Chiara Greggio, PhD¹²^*, Linda Favre-Kontula, PhD¹²^*, Lars Sternas, MD, PhD¹²^* and Jesús San-Miguel, MD, PhD¹³

¹Levine Cancer Institute, New York, NY
²Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
³Medical College of Wisconsin, Milwaukee, WI
⁴Sarah Cannon Research Institute, Nashville, TN
⁵Moffitt Cancer Center, Tampa, FL
⁶Washington University in St. Louis, St. Louis, MO
⁷Mass General Hospital Cancer Center, Boston, MA
⁸CHU La Milétrie, Poitiers, France
⁹Emory University, Atlanta, GA
¹⁰Columbia University Irving Medical Center, New York City, NY
¹¹2seventy bio, Cambridge, MA
¹²Bristol Myers Squibb, Princeton, NJ
¹³Clinica Universitaria de Navarra, Navarra, Spain

4:15 PM

362

Final Clinical Outcomes from a Phase 2 Trial of Posoleucel, an Off-the-Shelf, Multivirus-Specific T-Cell Therapy, for the Prevention of Clinically Significant Viral Infections Post-HCT

Sanjeet S Dadwal, MD¹, Jo-Anne H. Young, MD²^*, Michael W. Schuster, MD³, Jean A. Yared, MD⁴, Gary Douglas Myers, MD⁵^*, Michelle Matzko, MD, PhD⁶^*, Sama Adnan, PhD⁶^*, Joshua A. Hill, MD⁷^* and Rajat Bansal, MD⁸^*

¹Department of Infectious Disease, City of Hope National Medical Center, Duarte, CA
²Division of Infectious Diseases and International Medicine, University of Minnesota, Minneapolis, MN
³Stony Brook University Hospital Cancer Center, Stony Brook, NY
⁴Transplantation & Cellular Therapy Program, Division of Hematology/Oncology, Department of Internal Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, MD
⁵Children's Mercy of Kansas City, Kansas City, MS
⁶AlloVir, Waltham, MA
⁷Fred Hutchinson Cancer Research Center, Seattle, WA
⁸Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS

4:30 PM

363

Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Maria VD Soares, PhD¹^*, Virginia Escamilla Gomez²^*, Rita I Azevedo, PhD¹^*, Paulo N.G. Pereira, PhD¹^*, Teresa Caballero Velázquez, MD, PhD²^*, Clara B. Garcia-Calderón²^*, Kukatharmini Tharmaratnam³^*, Inês A Cabral, MSc¹^*, Ana C Ribeiro, MSc¹^*, Laura Mendes, MSc⁴^*, Clara Juncal, MD⁴^*, Susana Roncon, MD⁵^*, Ana Teresa Pais, MSc¹^*, Ana C Alho, MD^1,6^*, Alfonso Rodriguez Gil, PhD²^*, Eduardo L Espada, MD^1,6^*, Anabela Rodrigues, MD⁴^*, Ana Garção, MD⁴^*, Marie-Laure Yaspo, PhD⁷^*, Hans-Jörg Warnatz, PhD⁷^*, Hans Lehrach, PhD⁷^*, Nuno L. Barbosa-Morais, PhD⁸^*, Ana Miguel Quintas, MD⁹^*, Paulo Palmela, MD¹⁰^*, Cecilia Caldas, MD¹⁰^*, Rosa Ferreira, MD¹¹^*, Luis Leite, MD¹¹^*, Carlos Martins, MD⁶^*, Fernanda Lourenço, MD⁶^*, Raúl Moreno, MD⁶^*, João Raposo, MD¹²^*, Fernando Campilho, MD¹¹^*, Christopher Paul Cheyne, PhD³^*, Marta Garcia-Fiñana, PhD³^*, António Campos, MD¹¹^*, Frédéric Baron, MD, PhD¹³^*, Mario Arpinati, MD, PhD¹⁴, Matthias Edinger, MD, PhD¹⁵^*, Jerome Ritz, MD, PhD¹⁶, Carlos Pinho Vaz, MD¹¹^*, Jose A. Perez-Simon, MD, PhD¹⁷ and Joao F Lacerda, M.D., PhD^18,19

¹JLacerda Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa, Lisboa, Portugal
²Institute of Biomedicine of Seville (IBiS), University Hospital Virgen del Rocío of Sevilla, Sevilla, Spain
³Department of Health Data Science, University of Liverpool, Institute of Population Health, Liverpool, United Kingdom
⁴Serviço de Imuno-Hemoterapia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
⁵Serviço de Terapia Celular, Instituto Português de Oncologia do Porto FG, Porto, Portugal
⁶Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
⁷Max Planck Institute for Molecular Genetics, Berlin, Germany
⁸NMorais Lab, Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina Universidade de Lisboa, Lisboa, Portugal
⁹Serviço de Oftalmologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
¹⁰Serviço de Estomatologia, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
¹¹Serviço de Transplantação de Medula Óssea, Instituto Português de Oncologia do Porto, Porto, Portugal
¹²Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisboa, Portugal
¹³Division of Hematology, Department of Medicine, CHU of Liège, Liège, Belgium
¹⁴Institute of Hematology "Seràgnoli", S. Orsola-Malpighi University Hospital, University of Bologna, Bologna, Italy
¹⁵University Regensburg, Dept. of Hematology and Oncology, Regensburg, Germany
¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
¹⁷Instituto de Biomedicina de Sevilla (IBiS), UGC-Hematología, Hospital Universitario Virgen del Rocío/ CSIC/ CIBERONC, Universidad de Sevilla, Sevilla, Spain
¹⁸Serviço de Hematologia e Transplantação de Medula, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Lisbon, Portugal
¹⁹Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal

4:45 PM

364

Clinical Activity of BMS-986393 (CC-95266), a G Protein–Coupled Receptor Class C Group 5 Member D (GPRC5D)–Targeted Chimeric Antigen Receptor (CAR) T Cell Therapy, in Patients with Relapsed and/or Refractory (R/R) Multiple Myeloma (MM): First Results from a Phase 1, Multicenter, Open-Label Study

Susan Bal, MD¹^*, M. Hakan Kocoglu, MD², Omar Nadeem, MD³, Myo Htut, MD⁴, Tara Gregory, MD⁵^*, Larry D. Anderson Jr., MD, PhD⁶, Luciano J. Megala Costa, MD, PhD¹, Tonia J. Buchholz, MS, PhD⁷^*, Safiyyah Ziyad, PhD⁷^*, Meng Li, PhD⁷^*, Yanping Chen, PhD⁷^*, Allison J. Kaeding, MD⁷^*, Michael R. Burgess, MD, PhD⁷^*, Kristen Hege, MD⁷ and Jesus Berdeja, MD⁸

¹University of Alabama at Birmingham, Birmingham, AL
²University of Maryland, Baltimore, MD
³Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
⁴City of Hope Comprehensive Cancer Center, Duarte, CA
⁵Colorado Blood Cancer Institute, Sarah Cannon Cancer Network, Denver, CO
⁶Cellular Therapy and Hematologic Malignancies Program, Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, TX
⁷Bristol Myers Squibb, Princeton, NJ
⁸Sarah Cannon Research Institute, Nashville, TN

5:00 PM

365

Phase I Trial of CD8-Depleted Human Leukocyte Antigen (HLA) Mismatched Unrelated Donor Lymphocyte Infusion (DLI) to Achieve Remissions in Myelodysplastic Syndrome (MDS) and Secondary Acute Myeloid Leukemia (sAML)

Hany Elmariah, MD, MS¹, Jongphil Kim, PhD²^*, Kayla M. Reid, M.S.³^*, Christopher Cubitt, PhD⁴^*, Andrew Kuykendall, MD⁵, Jeffrey E. Lancet, MD⁵, Rami S. Komrokji⁵, David A. Sallman, MD⁶, Onyee Chan, MD⁵, Kendra Sweet, MD⁵, Albert J Ribickas⁷^*, Rawan Faramand, MD³, Asmita Mishra, MD³, Farhad Khimani, MD³^*, Lia Perez, MD¹^*, Debra Kessler, RN, MS⁸^*, Stephanie Dormesy, BA, MPH⁸^*, Joseph Pidala, MD, PhD³, Claudio Anasetti, MD³, Ephraim J. Fuchs, MD, MBA⁹, Michael D. Jain, MD, PhD³, Frederick L. Locke, MD³, Marco L. Davila, MD, PhD³, Nelli Bejanyan, MD³ and Amy E. DeZern, MD¹⁰

¹Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL
²Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institutte, Tampa, FL
³Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁴Immune Monitoring Core, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁵Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
⁶Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL
⁷H. Lee Moffitt Cancer Center and Research Institute, Tampa
⁸New York Blood Center, New York, NY
⁹Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
¹⁰Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

5:15 PM

366

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du¹^*, Weijun Fu², Jing Lu²^*, Wanting Qiang²^*, Haiyan He²^*, Jin Liu²^*, Ying Yang²^*, Zhongyuan Feng²^*, Lina Jin²^*, Xiaoqiang Fan²^*, Jia Liu³^*, Qi Zhang³^*, Lianjun Shen³^*, Lihong Weng³^* and Wei Cao³^*

¹Department of Hematology, Myeloma & Lymphoma Center, Shanghai Changzheng Hospital, The Second Military Medical University, Shanghai, China
²Department of Hematology, Myeloma & Lymphoma Center, Changzheng Hospital, Naval Medical University, Shanghai, China
³Gracell Biotechnologies Ltd., Shanghai, China

See more of: Oral and Poster Abstracts

<< Previous Session | Next Session >>

^*signifies non-member of ASH

704.O3.6 704. Cellular Immunotherapies: Early Phase and Investigational Therapies: CAR T in Multiple Myeloma and T-cell Therapies After Allo-HCT